Supplementary Figure 2 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with &lt;i&gt;AKT1&lt;/i&gt;&lt;sup&gt;E17K&lt;/sup&gt;-Mutant, ER-Positive Metastatic Breast Cancer